Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • About
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Metastatic Breast Cancer (MBC)”

233 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 233 results

Large-scale testing (Phase 3)UnknownNCT02383030
What this trial is testing

Fulvestrant as Maintenance Therapy After First-line Chemotherapy in HER2 - Postmenopausal MBC Patients

Who this might be right for
Metastatic Breast Cancer
Consorzio Oncotech 156
Not applicableStudy completedNCT06003114
What this trial is testing

Understand the Use of Palbociclib in Canadian Patients With Breast Cancer That Has Spread to Other Organs

Who this might be right for
Breast Cancer
Pfizer 472
Early research (Phase 1)Looking for participantsNCT06784193
What this trial is testing

Phase 1 Study of OP-3136 in Advanced or Metastatic Solid Tumors

Who this might be right for
Advanced or Metastatic ER+ HER2- Breast Cancer (mBC)Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)Advanced or Metastatic Castration-Resistant Prostate Cancer (mCRPC)+3 more
Olema Pharmaceuticals, Inc. 180
Testing effectiveness (Phase 2)UnknownNCT04143906
What this trial is testing

Vinorelbine/Carboplatin Versus Gemcitabine/Carboplatin in Metastatic Breast Cancer

Who this might be right for
Metastatic Breast Cancer
Shandong Cancer Hospital and Institute 200
Testing effectiveness (Phase 2)Study completedNCT01835236
What this trial is testing

Trastuzumab & Pertuzumab Followed by T-DM1 in MBC

Who this might be right for
Metastatic Breast Cancer
Swiss Cancer Institute 208
Large-scale testing (Phase 3)Ended earlyNCT03905343
What this trial is testing

Ribociclib-endocrine Combination Therapy Versus Chemotherapy as 1st Line in Visceral mBC

Who this might be right for
Breast Cancer
Swiss Cancer Institute 25
Not applicableStudy completedNCT05054166
What this trial is testing

Efficacy of Everolimus-containing Chemotherapy in HER2- mBC Patients With PI3K/AKT/mTOR Mutations Study

Who this might be right for
Breast CancerPI3K/AKT/mTOR Pathway MutationEverolimus
Zhejiang Cancer Hospital 14
Not applicableStudy completedNCT05392985
What this trial is testing

Detection and Analysis of MBC With Heterogeneous ER Expression

Who this might be right for
Breast Cancer
Fudan University 51
Not applicableUnknownNCT05550090
What this trial is testing

Dynamic Contrast-enhanced MRI Combined With IVIM-DWI for Early Prediction of Chemosensitivity in Liver MBC

Who this might be right for
Metastatic Breast Cancer in the Liver
Zhejiang Cancer Hospital 40
Not applicableStudy completedNCT01733628
What this trial is testing

Evaluation of Hypertension as a Predictor of Efficacy Bevacizumab in Metastatic Breast Cancer and Colorectal Cancer

Who this might be right for
Metastatic Colorectal CancerMetastatic Breast Cancer
Spanish Breast Cancer Research Group 143
Testing effectiveness (Phase 2)UnknownNCT03876587
What this trial is testing

Pyrotinib Combined With Docetaxel in the First-line Treatment of HER2-positive MBC

Who this might be right for
Metastatic Breast Cancer
Zhejiang Cancer Hospital 79
Large-scale testing (Phase 3)Active Not RecruitingNCT04964934
What this trial is testing

Phase III Study to Assess AZD9833+ CDK4/6 Inhibitor in HR+/HER2-MBC With Detectable ESR1m Before Progression (SERENA-6)

Who this might be right for
ER-Positive HER2-Negative Breast Cancer
AstraZeneca 315
Testing effectiveness (Phase 2)Looking for participantsNCT07007559
What this trial is testing

ASPEN-09-03: A Study of Evorpacept in Combination With Trastuzumab and Chemotherapy in Metastatic HER2-Positive Breast Cancer

Who this might be right for
Breast Cancer, Metastatic
ALX Oncology Inc. 120
Large-scale testing (Phase 3)Active Not RecruitingNCT03315364
What this trial is testing

Oral Paclitaxel Trial In Recurrent and Metastatic Breast Cancer As 1st Line Therapy

Who this might be right for
Recurrent or Metastatic Breast Cancer
Daehwa Pharmaceutical Co., Ltd. 549
Not applicableLooking for participantsNCT06033287
What this trial is testing

Real-World Study on CDK4/6 Inhibitors Combined With Endocrine Therapy and Subsequent Treatment in HR+/HER2- MBC.

Who this might be right for
Breast CancerEndocrine TherapyCDK4/6 Inhibitors+1 more
Hunan Cancer Hospital 300
Testing effectiveness (Phase 2)Ended earlyNCT01495247
What this trial is testing

Phase Ib/II Trial of BEZ235 With Paclitaxel in Patients With HER2 Negative, Locally Advanced or Metastatic Breast Cancer

Who this might be right for
Inoperable Locally Advanced Breast CancerMetastatic Breast Cancer (MBC)
Novartis Pharmaceuticals 18
Large-scale testing (Phase 3)Ended earlyNCT03326674
What this trial is testing

Tesetaxel Plus Reduced Dose of Capecitabine vs. Capecitabine in HER2 Negative, HR Positive, LA/MBC

Who this might be right for
Breast Cancer
Odonate Therapeutics, Inc. 685
Not applicableUnknownNCT02365831
What this trial is testing

Observation of Medical Treatments in MBC HER2-negative Patients

Who this might be right for
Metastatic Breast Cancer
Consorzio Oncotech 1,500
Large-scale testing (Phase 3)Study completedNCT03901339
What this trial is testing

Study of Sacituzumab Govitecan-hziy Versus Treatment of Physician's Choice in Participants With HR+/HER2- Metastatic Breast Cancer

Who this might be right for
Metastatic Breast Cancer
Gilead Sciences 543
Testing effectiveness (Phase 2)UnknownNCT02175446
What this trial is testing

Safety and Efficacy Study of Eribulin in Combination With Bevacizumab for Second-line Treatment HER2- MBC Patients

Who this might be right for
Metastatic Breast CancerHuman Epidermal Growth Factor 2 Negative Carcinoma of Breast
Consorzio Oncotech 61
Load More Results